Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia.

Although immunosuppressive therapy (IST) with cyclosporine A (CyA) has been widely used in patients with aplastic anemia (AA), little attention has been given to its safety. This study aimed to clarify the adverse events of IST in patients with AA. We retrospectively identified 42 patients with AA treated with IST. Seventeen of the 42 patients (40%) experienced severe infection at a median of 142 days from the start of IST, and 18 (49%) experienced renal dysfunction at a median of 73 days. A large proportion of infected patients had severe AA (90 vs. 14%, p = 0.056). Notably, all patients with severe infection showed poor response to IST at the time of infection onset. Analysis regarding risk factors for renal dysfunction showed that median age at the initiation of IST was significantly higher in patients with renal dysfunction than those without renal dysfunction (65 years vs. 44 years, p = 0.020). Only 2 of 18 patients showed improvement in serum creatinine levels despite reduction or discontinuation of CyA. Our results suggest that poor responders to IST and elderly patients are at higher risk of severe infection and renal dysfunction, respectively.